Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

"Two things at once," the Kansas City Chiefs player repeats in the ad, as he promotes getting both shots in one sitting. Travis Kelce stars in a Pfizer commercial backing both the COVID-19 and flu ...

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...